Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1495-1503

  Clarke, S J ^a   Hanwell, J ^a   de Boer, M ^a   Planting, A ^a   Verweij, J ^a   Walker, M ^a   Smith, R ^a   Jackman, A L ^a   Hughes, L R ^a   Harrap, K R ^a   Kennealey, G T ^a   Judson, I R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RALTITREXED;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 9244240774     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1495     Document Type: Article

References (32)

1. 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4:1245-1252, 1986
2. 10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur J Cancer Clin Oncol 24:733-736, 1988
3. Bassendine MF, Curtin NJ, Loose H, et al: Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. J Hepatol 4:349-356, 1987
4. 10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer 57:628-629, 1988
5. 10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 70:1335-1336, 1986
6. 10-propargyl-5,8 dideazafolic acid (CB3717). Cancer Chemother Pharmacol 14:265-271, 1985
7. 10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat Rep 70:971-979, 1986
8. Jones TR, Thornton TJ, Flinn A, et al: Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem 32:847-852, 1989
9. Hughes LR, Jackman AL, Oldfield J, et al: Quinazoline antifolate thymidylate synthase inhibitors: Alkyl, substituted alkyl, and aryl substituents in the C2 position. J Med Chem 33:3060-3067, 1990
10. Marsham PR, Hughes LR, Jackman AL, et al: Quinazoline antifolate thymidylate synthase inhibitors: Heterocyclic benzoyl ring modifications. J Med Chem 34:1594-1605, 1991
11. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol 42:1885-1895, 1991
12. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res 50:5212-5218, 1990
13. 10-substituted-5,8-dideazafolates. Adv Enzyme Regul 31:13-27, 1991
14. Jackman AL, Taylor GA, Gibson W, et al: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent of L1210 tumour cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586, 1991
15. Jodrell DI, Newell DR, Gibson W, et al: The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemother Pharmacol 28:331-338, 1991
16. Jackman AL, Jodrell DI, Gibson W, et al: ICI D1694, an inhibitor of thymidylate synthase for clinical study, in Harkness RA, Elion GB, Zollner N (eds): Purine and Pyrimidine Metabolism in Man VII. New York, NY, Plenum, 1991, pp 19-23
17. 10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer 64:833-838, 1991
18. Hayward JL, Rubens RD, Carbone PP, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298, 1977
19. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
20. Whiting-O'Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 90:711-716, 1991
21. Warkentin P, Coccia P, Ramsay N, et al: Acute hepatocellular injury after high dose methotrexate (MTX) infusions. Proc Am Assoc Cancer Res 20:98, 1979 (abstr)
22. Weber BL, Tanyer G, Poplack DG, et al: Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. Natl Cancer Inst Monogr 5:207-212, 1987
23. Kris MG, Kinahan JJ, Gralla RJ, et al: Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res 48:5573-5579, 1988
24. Weiss GR, Sarosy GA, Shenkenberg TD, et al: A phase I trial clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). Eur J Cancer Clin Oncol 25:1867-1873, 1989
25. Fanucchi MP, Walsh TD, Fleisher M, et al: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303-3308, 1987
26. Grem JL, Shoemaker DD, Petrelli NJ, et al: Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma. Cancer Treat Rep 71:1122, 1987
27. Kennedy P, Presant CA, Blayney D, et al: Sandostatin therapy for chemotherapy and radiotherapy related diarrhea. Proc Am Soc Clin Oncol 9:324, 1990 (abstr)
28. Cascinu S, Fedeli A, Fedeli SL, et al: Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. J Clin Oncol 11:148-151, 1993
29. Cascinu S, Fedeli A, Fedeli SL, et al: Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5 fluorouracil. Eur J Cancer Clin Oncol 28:482-483, 1992
30. Cunningham D, Zalcberg J, Smith IE, et al: Tomudex: A novel thymidylate synthase (TS) inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 5:179, 1994 (suppl 8)
31. Zalcberg J, Cunningham D, Green M, et al: Final results of a large phase II study of the potent thymidylate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. Proc Am Soc Ciln Oncol 14:204, 1995 (abstr)
32. Cunningham D, Zalcburg J, Rath U, et al: 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A:1945-1954, 1995